{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:01:02Z","timestamp":1772643662136,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The purpose of the present study was to evaluate outcomes with radiation therapy (RT) in multimodality treatment for inoperable hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The present retrospective study included 24 patients without extrahepatic metastases. The patients had received drug eluting beads - transarterial chemoembolization (DEB-TACE) (n\u2009=\u200910) and systemic treatment (n\u2009=\u200914) before RT. The dose fractionation was 12\u201331.5\u2009Gy in 3\u20137 fractions of 4\u20135\u2009Gy to PVTT or PVTT plus the liver parenchymal tumour. All patients were advised systemic treatment with sorafenib, lenvatinib, or nivolumab after RT. After RT, patients had received DEB-TACE within 8\u2009weeks (n\u2009=\u20092) or at 5\u201310\u2009months (n\u2009=\u20093). Treatment response was evaluated as per mRECIST and PERCIST, and Kaplan-Meier survival analysis was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The disease control rate in PVTT was 50% at 3\u2009months. The median overall survival (OS) was 10.9\u2009months (95% CI, 0.74-21) for all patients. The 6-month, 1-year, 2-year, and 3-year OS rates were 75%, 45.8%, 25%, and 12.5%, respectively. The median OS was 30.4\u2009months (95% CI, 12.1-48.7) versus 18.1\u2009months (0.00-38.8) with complete or partial response versus stable or progressive disease in PVTT (P\u2009=\u2009.036). Eleven patients had a decline in Child Pugh score of 2 or more points within 3\u2009months after RT. One patient underwent live donor liver transplantation (LDLT) and complete necrosis with no viable tumour was observed in the explant. The patient is cancer- and liver disease-free at 1\u2009year after LDLT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The present study showed the benefit of radiotherapy with systemic therapy and DEB-TACE in patients with HCC with PVTT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>Radiotherapy as part of the multimodality treatment offers the potential to improve disease control and survival in patients with HCC with PVTT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjro\/tzaf002","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:33:31Z","timestamp":1739907211000},"source":"Crossref","is-referenced-by-count":7,"title":["Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-7398","authenticated-orcid":false,"given":"Puja","family":"Sahai","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanuman Prasad","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saggere Muralikrishna","family":"Shasthry","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Jindal","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aprajita","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Mukund","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-3190","authenticated-orcid":false,"given":"Yashwant","family":"Patidar","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangu Srinivas","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangkim Chandra","family":"Khangembam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viniyendra","family":"Pamecha","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreatobiliary and Liver Transplant Surgery, Institute of Liver and Biliary Sciences , New Delhi 110070,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025031512063963500_tzaf002-B1"},{"key":"2025031512063963500_tzaf002-B2","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1097\/MD.0000000000003015","article-title":"Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025031512063963500_tzaf002-B3","doi-asserted-by":"publisher","first-page":"oyae209","DOI":"10.1093\/oncolo\/oyae209","article-title":"Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis","author":"Ma","year":"2024","journal-title":"Oncologist"},{"key":"2025031512063963500_tzaf002-B4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/cancers15010050","article-title":"Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025031512063963500_tzaf002-B5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"2025031512063963500_tzaf002-B6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"2025031512063963500_tzaf002-B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"Suppl 1","key":"2025031512063963500_tzaf002-B8","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"2025031512063963500_tzaf002-B9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13014-021-01874-7","article-title":"Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus","volume":"16","author":"Zhang","year":"2021","journal-title":"Radiat Oncol"},{"key":"2025031512063963500_tzaf002-B10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12072-021-10173-y","article-title":"Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"Li","year":"2021","journal-title":"Hepatol Int"},{"key":"2025031512063963500_tzaf002-B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctro.2017.04.003","article-title":"Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus","volume":"4","author":"Holliday","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025031512063963500_tzaf002-B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13014-023-02270-z","article-title":"Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study","volume":"18","author":"Ji","year":"2023","journal-title":"Radiat Oncol"},{"key":"2025031512063963500_tzaf002-B13","doi-asserted-by":"publisher","first-page":"9575","DOI":"10.1038\/s41598-020-66583-9","article-title":"Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters","volume":"10","author":"Hsieh","year":"2020","journal-title":"Sci Rep"},{"key":"2025031512063963500_tzaf002-B14"},{"key":"2025031512063963500_tzaf002-B15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/cancers16051058","article-title":"Immunotherapy and radiation therapy combinatorial approaches in hepatocellular carcinoma","volume":"16","author":"Tojjari","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025031512063963500_tzaf002-B16","doi-asserted-by":"publisher","first-page":"882","DOI":"10.21037\/hbsn-23-134","article-title":"Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors","volume":"12","author":"Ning","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025031512063963500_tzaf002-B17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s12885-021-08469-1","article-title":"Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"2025031512063963500_tzaf002-B18","doi-asserted-by":"publisher","first-page":"6017406","DOI":"10.1155\/2016\/6017406","article-title":"Efficacy of external beam radiation-based treatment plus locoregional therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis","volume":"2016","author":"Chen","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025031512063963500_tzaf002-B19","doi-asserted-by":"publisher","first-page":"e0268779","DOI":"10.1371\/journal.pone.0268779","article-title":"Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: a meta-analysis","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"key":"2025031512063963500_tzaf002-B20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S1470-2045(24)00438-8","article-title":"Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study","volume":"25","author":"Dawson","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025031512063963500_tzaf002-B21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12664-021-01172-w","article-title":"Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: interim results of a prospective study","volume":"40","author":"Dutta","year":"2021","journal-title":"Indian J Gastroenterol"},{"key":"2025031512063963500_tzaf002-B22","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/RLU.0000000000001422","article-title":"Prognostic value of FDG uptake of portal vein tumor thrombosis in patients with locally advanced hepatocellular carcinoma","volume":"42","author":"Lee","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2025031512063963500_tzaf002-B23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3349\/ymj.2016.57.5.1276","article-title":"Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy","volume":"57","author":"Han","year":"2016","journal-title":"Yonsei Med J"},{"key":"2025031512063963500_tzaf002-B24","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1038\/s41598-020-60871-0","article-title":"Preoperative stereotactic body radiotherapy to portal vein tumour thrombus in hepatocellular carcinoma: clinical and pathological analysis","volume":"10","author":"Kishi","year":"2020","journal-title":"Sci Rep"},{"key":"2025031512063963500_tzaf002-B25","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.3748\/wjg.v23.i43.7735","article-title":"Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"23","author":"Zhang","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025031512063963500_tzaf002-B26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.brachy.2023.06.229","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"22","author":"Lin","year":"2023","journal-title":"Brachytherapy"},{"key":"2025031512063963500_tzaf002-B27","doi-asserted-by":"publisher","first-page":"1533033818790217","DOI":"10.1177\/1533033818790217","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies","volume":"17","author":"Schaub","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"2025031512063963500_tzaf002-B28","doi-asserted-by":"publisher","first-page":"20130147","DOI":"10.1259\/bjr.20130147","article-title":"Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours","volume":"86","author":"Lausch","year":"2013","journal-title":"Br J Radiol"},{"key":"2025031512063963500_tzaf002-B29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025031512063963500_tzaf002-B30","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BJR|Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjro\/advance-article-pdf\/doi\/10.1093\/bjro\/tzaf002\/61945029\/tzaf002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf002\/61945029\/tzaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjro\/article-pdf\/7\/1\/tzaf002\/61945029\/tzaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:06:48Z","timestamp":1742040408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjro\/article\/doi\/10.1093\/bjro\/tzaf002\/8020793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjro\/tzaf002","relation":{},"ISSN":["2513-9878"],"issn-type":[{"value":"2513-9878","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,27]]},"article-number":"tzaf002"}}